Skip to main content

Table 1 Main characteristics of included studies in this NMA

From: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

First Author

Year

Country

Ethnicity

Interventions

Sample Size

Age, y

T1

T2

T3

Total

T1

T2

T3

T1

T2

T3

Chen F [20]

2017

China

Asians

K

O

—

107

47

60

—

67 (60–80)

68 (60–80)

—

Liang J [21]

2017

China

Asians

A

M

—

191

95

96

—

NR

NR

—

Feng JF [22]

2016

China

Asians

F

I

—

72

36

36

—

63 (42–84)

62 (42–83)

—

Sen F [23]

2016

Turkey

Caucasians

A

E

—

105

50

55

—

54 (32–70)

55 (37–73)

—

Senan S [24]

2016

USA

Caucasians

D

A

—

555

283

272

—

58.7 (34.6–80.4)

59.5 (28.0–83.7)

—

Zhao Q [25]

2016

China

Asians

H

D

—

100

48

52

—

57.4 (34–73)

60.3 (40–75)

—

Yao L [26]

2015

China

Asians

F

I

—

40

20

20

—

59.6 (40.3–78.9)

60.4 (40.3–80.5)

—

Liew MS [27]

2013

Australia

Caucasians

B

A

—

75

44

31

—

71 (44–83)

63 (32–76)

—

Sugawara S [28]

2013

Japan

Asians

F

H

—

66

35

31

—

NR

NR

—

Atagi S [29]

2012

Japan

Asians

K

R

—

197

98

99

—

77 (71–93)

77 (71–89)

—

Wang LH [30]

2012

China

Asians

A

B

—

65

33

32

—

55.4 (26–77)

60.9 (40–75)

—

John H [31]

2010

USA

Caucasians

C

D

—

22

9

13

—

62 (46–74)

60 (43–84)

—

Segawa Y [32]

2010

Japan

Asians

E

G

—

200

99

101

—

NR

NR

—

Yamamoto N [33]

2010

Japan

Asians

G

N

B

456

153

152

151

63.3 (31–74)

62 (30–74)

63.0 (38–74)

Atagi S [34]

2005

Japan

Asians

K

R

—

46

23

23

—

77 (72–84)

77 (71–83)

—

Cakir S [35]

2004

Turkey

Caucasians

K

I

—

176

88

88

—

61 (47–70)

60 (46–70)

—

Sarihan S [36]

2004

Turkey

Caucasians

K

Q

—

41

20

21

—

63 (37–77)

55 (36–68)

—

Komaki R [37]

2002

USA

Caucasians

J

A

—

53

27

26

—

62 (37–77)

64 (43–74)

—

Ball D [38]

1999

Australia

Caucasians

K

R

—

107

53

54

—

65 (40–78)

66 (46–77)

—

Ball D [39]

1997

Australia

Caucasians

K

L

—

200

101

99

—

67 (40–91)

67 (42–86)

—

Jeremic B [40]

1996

Japan

Asians

K

P

—

131

66

65

—

58 (46–65)

59 (42–67)

—

Trovo MG [41]

1992

Italy

Caucasians

K

I

—

173

88

85

—

61 (43–70)

62 (36–69)

—

  1. A, CCRT (cisplatin + etoposide); B, CCRT (carboplatin + paclitaxel); C, CCRT (pemetrexed + carboplatin); CCRT, concurrent chemoradiotherapy; D, CCRT (pemetrexed + cisplatin); E, CCRT (docetaxel + cisplatin); F, CCRT (S-1 + cisplatin); G, CCRT (mitomycin + vindesine + cisplatin); H, CCRT (cisplatin + vinorelbine); I, CCRT (cisplatin); J, CCRT (etoposide + cisplatin + amifostine); K, RT; L, CCRT (5-FU); M, CCRT (paclitaxel + cisplatin); N, CCRT (irinotecan + carboplatin); NMA Network meta-analysis, NR Not report; O, CCRT (nedaplatin); P, CCRT (carboplatin + etoposide); Q, CCRT (paclitaxel); R, CCRT (carboplatin)